203047-33-0

Basic information

• Product Name: TERT-BUTYL 4-(3-NITROBENZYL)PIPERAZINE-1-CARBOXYLATE
• Synonyms: TERT-BUTYL 4-(3-NITROBENZYL)PIPERAZINE-1-CARBOXYLATE;TERT-BUTYL 4-(3-NITROBENZYL)TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE;BUTTPARK 99\06-10;4-(3-NITROBENZYL)PIPERAZINE, N1-BOC PROTECTED;4-(3-Nitrobenzyl)piperazine, N1-BOC protected 97%;N1-BOC-4-(3-NITROBENZYL)PIPERAZINE;1-Boc-4-(3-Nitrobenzyl)piperazine;4-(3-Nitrobenzyl)piperazine,N1-BOCprotected97%
• CAS NO: 203047-33-0
• Molecular Formula: C₁₆H₂₃N₃O₄
• Molecular Weight: 321.37
• Mol File: 203047-33-0.mol
• Article Data: 6

Chemical Properties

• Melting Point: 84 °C
• Boiling Point: 434.5 °C at 760 mmHg
• Flash Point: 216.6 °C
• Appearance: /
• Density: 1.208 g/cm³
• Vapor Pressure: 9.39E-08mmHg at 25°C
• Refractive Index: 1.561
• PKA: 5.74±0.10(Predicted)
• CAS DataBase Reference: TERT-BUTYL 4-(3-NITROBENZYL)PIPERAZINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-(3-NITROBENZYL)PIPERAZINE-1-CARBOXYLATE(203047-33-0)
• EPA Substance Registry System: TERT-BUTYL 4-(3-NITROBENZYL)PIPERAZINE-1-CARBOXYLATE(203047-33-0)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 203047-33-0(Hazardous Substances Data)

Usage

General Description

Tert-butyl 4-(3-nitrobenzyl)piperazine-1-carboxylate is a compound with the molecular formula C18H23N3O4. It is an ester derivative of piperazine and is commonly used in organic synthesis and pharmaceutical research. The compound has a tert-butyl group attached to the piperazine ring, as well as a nitrobenzyl group, making it useful for the modification and study of piperazine derivatives. It is a potential precursor in the synthesis of various pharmaceuticals and has shown potential pharmacological activity in research studies.

InChI:InChI=1/C16H23N3O4/c1-16(2,3)23-15(20)18-9-7-17(8-10-18)12-13-5-4-6-14(11-13)19(21)22/h4-6,11H,7-10,12H2,1-3H3

Upstream product

• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 203047-37-4 1-[(3-nitrophenyl)methyl]piperazine 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 3958-57-4 1-bromomethyl-3-nitrobenzene 
• 99-61-6 3-nitro-benzaldehyde 

Downstream Products

• 361345-40-6 tert-butyl 4-[(3-aminophenyl)methyl]piperazine-1-carboxylate 
• 203047-37-4 1-[(3-nitrophenyl)methyl]piperazine 

Relevant articles and documents

Discovery of Orally Available Retinoic Acid Receptor-Related Orphan Receptor γ-t/Dihydroorotate Dehydrogenase Dual Inhibitors for the Treatment of Refractory Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is a multifactorial autoimmune disease, representing a major clinical challenge. Herein, a strategy of dual-targeting approach employing retinoic acid receptor-related orphan receptor γ-t (RORγt) and dihydroorotate dehydrogenase (DHODH) was proposed for the treatment of IBD. Dual RORγt/DHODH inhibitors are expected not only to reduce RORγt-driven Th17 cell differentiation but also to mitigate the expansion and activation of T cells, which may enhance anti-inflammatory effects. Starting from 2-aminobenzothiazole hit 1, a series of 2-aminotetrahydrobenzothiazoles were discovered as potent dual RORγt/DHODH inhibitors. Compound 14d stands out with IC50 values of 0.110 μM for RORγt and of 0.297 μM for DHODH. With acceptable mouse pharmacokinetic profiles, 14d exhibited remarkable in vivo anti-inflammatory activity and dose-dependently alleviated the severity of dextran sulfate sodium (DSS)-induced acute colitis in mice. Taken together, the present study provides a novel framework for the development of therapeutic agents for the treatment of IBD.

1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to novel compounds represented by the formula I having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. (I) The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases.

AMINE COMPOUNDS

The present invention provide a compound of the formula:wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 and R5 are the same or different and each represents a hydrogen, etc.; R6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.